

1. Wielińska J, Bugaj B, Świerkot J, et al. Association of MICA and NKG2D genetic variants with disease susceptibility and outcome of anti-TNF therapy in patients with axial spondyloarthritis. *Clin Exp Rheumatol*. 2024 Feb 12.
2. Leng X, Leszczyński P, Jeka S, et al. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial. *Lancet Rheumatol*. 2024 Jan;6(1):e40-e50.
3. Schmalzing M, Kellner H, Askari A, et al. Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study. *Adv Ther*. 2024 Jan;41(1):315-330. (MNiSW: 70; IF: 3,800)
4. Stajszczyk M, Obarska I, Jeka S, et al. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database. *Ann Rheum Dis*. 2023 Sep;82(9):1171-1180. (MNiSW: 200; IF: 27,400)
5. Reinisch W, Hellstrom W, Dolhain RJEM, et al. Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAY studies. *Ann Rheum Dis*. 2023 Aug;82(8):1049-1058. (MNiSW: 200; IF: 27,400)
6. Wiciński M, Szwedowski D, Wróbel Ł, et al. The Influence of Body Mass Index on Growth Factor Composition in the Platelet-Rich Plasma in Patients with Knee Osteoarthritis. *Int J Environ Res Public Health*. 2022 Dec 20;20(1):40. (MNiSW: 20; IF: 0)
7. Biały S, Iwaszko M, Świerkot J, et al. Th2 Cytokines (Interleukin-5 and -9) Polymorphism Affects the Response to Anti-TNF Treatment in Polish Patients with Ankylosing Spondylitis. *Int J Mol Sci*. 2022 Oct 29;23(21):13177. (MNiSW: 140; IF: 5,600)
8. Stajszczyk M, Jeka S, Juś A, et al. Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the

- multicenter observational ACT-POL study. *Reumatologia* 2022; 60, 2: 92–100. (MNiSW: 70; IF: 0)
9. Batko B, Jeka S, Wiland P, et al. Deep dive into achieving the therapeutic target: results from a prospective, 6-month, observational study nested in routine rheumatoid arthritis care. *Pol Arch Intern Med.* 2022 Apr 14;16244. (MNiSW 140; ; IF: 5,218)
  10. Iwaszko M, Wielińska J, Świerkot J, et al. IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients. *Front Immunol.* 2021 Jun 11;12:631603. doi: 10.3389/fimmu.2021.631603. (MNiSW 140; ; IF: 7,561)
  11. Furst DE, Jaworski J, Wojciechowski R, et al. Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomised study in rheumatoid arthritis. *Rheumatology (Oxford).* 2021 Jun 17;keab460. doi: 10.1093/rheumatology/keab460. Online ahead of print. (MNiSW 140; ; IF: 5,606)
  12. Szwedowski D, Szczepanek J, Paczesny Ł, et al. The effect of platelet-rich plasma on the intra-articular : microenvironment in knee osteoarthritis. *Int. J. Mol. Sci.* 2021; 22(11): 1-13. (MNiSW 140: ; IF: 4,556)
  13. McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. *N Engl J Med.* 2021; 384(13): 1227-1239. (MNiSW 200: ; IF: 74,699)
  14. Kay J, Jaworski J, Wojciechowski R, et al. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. *Arthritis Res Ther.* 2021; 23(1): 51. (MNiSW 140: ; IF: 4,103)
  15. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. *Ann Rheum Dis.* 2020: 2020-218808. (MNiSW: 200; IF: 16,102)
  16. Wiland P, Jeka S, Dokoupilová E, et al. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. *BioDrugs.* 2020; 34(6): 809-823. (MNiSW: 100; IF: 5,313)
  17. Wielińska J, Kolossa K, Świerkot J, et al. Polymorphisms within the RANK and RANKL Encoding Genes in Patients with Rheumatoid Arthritis: Association with Disease Progression and Effectiveness of the Biological Treatment. *Arch Immunol Ther Exp (Warsz).* 2020; 68(4): 24. (MNiSW: 70; IF: 3,200)

18. Góralczyk A, Kolossa K, Waszczak-Jeka M, et al. The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation. *Postepy Dermatol Alergol.* 2020; 37(3): 306-312. (MNiSW: 70; IF: 1,361)
19. Dura M, Żuchowski P, Gorgolewski P, et al. The changing role of ultrasonography examination in patients with rheumatoid arthritis in light of recent studies. *Reumatologia* 2020; 58(3):155-161. (MNiSW: 20; IF: 0)
20. Cohen S, Tuckwell K, Katsumoto TR, et al. Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study). *Arthritis Rheumatol.* 2020 Apr 9. doi: 10.1002/art.41275. [Epub ahead of print] (MNiSW: 200; IF: 9,002)
21. Iwaszko M, Świerkot J, Dratwa M, et al. Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis. *Pharmacogenomics J.* 2020 Mar 3. doi: 10.1038/s41397-020-0164-3. [Epub ahead of print] (MNiSW: 140; IF: 3,503)
22. Sierakowska M, Doroszkiewicz H, Sierakowska J, et al. Factors associated with quality of life in systemic sclerosis: a cross-sectional study. *Qual Life Res.* 2019 Dec; 28(12): 3347-3354. (MNiSW: 100; IF: 2,488)
23. Shim SC, Bozić-Majstorović L, Berrocal Kasay A, et al. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. *Rheumatology (Oxford).* 2019;58(12): 2193-2202. (MNiSW: 140; IF: 5,149)
24. Napiórkowska-Baran K, Zalewska J, Jeka S, et al. Determination of antibodies in everyday rheumatological practice. *Reumatologia.* 2019; 57(2): 91-99. (MNiSW: 20; IF: 0)
25. Żuchowski P, Waszczak-Jeka M, Kudlicki S, et al. The rheumatoid hand in the light of fluorescence: a diagnostic technique of the future? *Reumatologia.* 2019; 57(1):45-49. (MNiSW: 20; IF: 0)
26. Suh CH, Yoo DH, Berrocal Kasay A, et al. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial. *BioDrugs.* 2019; 33(1): 79-91. (MNiSW: 100; IF: 4,903)
27. Tony HP, Kruger K, Cohen S, et al. Safety and Immunogenicity of Rituximab Biosimilar GP2013 After Switch from Reference Rituximab in Patients with Active

- Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2019; 71(1): 88-94. (MNiSW: 140; IF: 4,530)
28. Kowalik K, Węgierska M, Barczyńska T, et al. Pharmacoeconomic evaluation of treatment effectiveness with selected biologic treatment in rheumatoid arthritis therapy. *Reumatologia*. 2018; 56(4): 212-218. (MNiSW: 14; IF: 0)
  29. Kucharz EJ, Stajszczyk M, Kotulska-Kucharz A, et al. Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. *Reumatologia*. 2018; 56(4): 203-211. (MNiSW: 14; IF: 0)
  30. Jeka S, Dura M, Zuchowski P, et al. The role of ultrasonography in the diagnostic criteria for rheumatoid arthritis and monitoring its therapeutic efficacy. *Adv Clin Exp Med*. 2018; 27(9):1303-1307. (MNiSW: 15; IF: 1,227)
  31. Park W, Bozić-Majstorović 2, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. *MAbs*. 2018; 10(6): 934-943. (MNiSW: 40; IF: 4,405)
  32. Zalewska J, Napiórkowska-Baran K, Pałgan K, et al. Zespół aktywacji makrofagów (macrophage activation syndrome, MAS) w przebiegu układowych chorób tkanki łącznej. *Alergia Astma Immunol*. 2018; 23(1): 7-13. (MNiSW: 9; IF: 0)
  33. Jeka S, Batko B, Korkosz M, et al. Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs: Results of the GO-MORE study in the Polish population. *Adv Clin Exp Med*. 2018; 27(4): 493-499. (MNiSW: 15; IF: 1,227)
  34. Iwaszko M, Świerkot J, Kolossa K, et al. Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. *Genes (Basel)*. 2018;9(2). (MNiSW: 25; IF: 3,331)
  35. Mease PJ, Jeka S, Jaller JJ, et al. CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebocontrolled, Phase II, Dose-ranging Study. *J Rheumatol*. 2018; 45(1): 22-31. (MNiSW: 30; IF: 3,634)
  36. Jeka S, Dura M, Żuchowski P, et al. The role of ultrasonography in monitoring long-standing rheumatoid arthritis: a pilot study. *Reumatologia*. 2017; 55(4): 177-182. (MNiSW: 14; IF: 0)
  37. Yoo DH, Suh CH, Shim SC, et al. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients

- with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial. *BioDrugs* 2017; 31(4): 357-367. (MNiSW: 30; IF: 3,825)
38. Park W, Suh CH, Shim SC, et al. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. *BioDrugs*. 2017; 31(4):369-377. (MNiSW: 30; IF: 3,825)
39. Guła Z, Barczyńska T, Brzosko M, et al. Results from Polish Spondyloarthritis Initiative registry (PolSPI) - methodology and data from - the first year of observation. *Reumatologia* 2017; 55(2): 59-64. (MNiSW: 14; IF: 0)
40. Yoo DH, Suh CH, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2017; 76(3): 566-570. (MNiSW: 45; IF: 12,350)
41. Jeka S, Dura M. Reumatyzm tkanek miękkich. *Reumatologia* 2016, suplement 1; 54, 1. (MNiSW: 4; IF: 0)
42. Sierakowska M, Klepacka M, Sierakowski SJ, et al. Assessment of education requirements for patients with rheumatoid arthritis, based on the Polish version of the Educational Needs Assessment Tool (Pol-ENAT), in the light of some health problems - A cross-sectional study. *Ann Agric Environ Med*. 2016; 23(2): 361-367. (MNiSW: 20; IF: 0,829)
43. Węgierska M, Dura M, Blumfield E, et al. Osteoporosis diagnostics in patients with rheumatoid arthritis. *Reumatologia* 2016; 54(1): 29-34. (MNiSW: 14; IF: 0)
44. Zalewska J, Węgierska M, Barczyńska T, et al. Efficacy of radiation synovectomy (radiosynovectomy or radiosynoviorthesis) with yttrium-90 in exudative inflammation of synovial membrane of knee joints in patients with rheumatic diseases - preliminary report. *Reumatologia* 2016; 54(1): 3-9. (MNiSW: 14; IF: 0)
45. Iwaszko M, Świerkot J, Kolossa K, et al. Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment. *Joint Bone Spine*. 2016; 83(1): 75-79. (MNiSW: 25; IF: 3,329)
46. Wallace DJ, Hobbs K, Clowse ME, et al. Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study. *Arthritis Care Res (Hoboken)*. 2016; 68(4): 534-543. (MNiSW: 35; IF: 3,319)

47. Iwaszko M, Świerkot J, Kolossa K, et al. Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy. *Clin Exp Immunol.* 2015; 182(3): 270-277. (MNiSW: 30; IF: 3,148)
48. Barczyńska TA, Węgierska M, Żuchowski P, et al. Coexistence of rheumatoid arthritis and ankylosing spondylitis. *Reumatologia* 2015; 53(5): 279–285. (MNiSW: 14; IF: 0)
49. Żuchowski P, Kolossa K, Jeka S, et al. Assessment of the usefulness of skin autofluorescence as an indicator of disease activity and of the risk of developing diabetes in patients suffering from rheumatoid arthritis. *Reumatologia* 2015; 53(5): 247-251. (MNiSW: 14 IF: 0)
50. Barczyńska TA, Dura M, Blumfield E, et al. DAS28 score vs. ultrasound examination for assessment of rheumatoid arthritis disease activity: comparison and discussion of pros and cons. *Reumatologia* 2015; 53(4): 213–218. (MNiSW: 14; IF: 0)
51. Sudoł-Szopińska I, Urbanik A, Wojciechowski W, et al. Polish Medical Society of Radiology and Polish Society of Rheumatology recommendations for magnetic resonance imaging of musculoskeletal disorders in rheumatology. *Reumatologia* 2015; 53(4): 171-178. (MNiSW: 0; IF: 0)
52. Bielewicz-Zielińska A, Brzezicki J, Rymko, et al. Unusual location of tuberculosis in the course of tumor necrosis factor  $\alpha$  inhibitor therapy. *Reumatologia* 2015; 53(3): 161-164. (MNiSW: 14; IF: 0)
53. Sudoł-Szopińska I, Urbanik A, Wojciechowski W, et al. Polish Medical Society of Radiology and Polish Society of Rheumatology Recommendations for Magnetic Resonance Imaging of Musculoskeletal Disorders in Rheumatology. *Pol J Radiol.* 2015; 80: 259-265. (MNiSW: 15; IF: 0)
54. Swierkot J, Bogunia-Kubik K, Nowak B, et al. Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. *Joint Bone Spine.* 2015; 82(2): 94-99. (MNiSW: 25; IF: 2,946)
55. Jeka S, Żuchowski P, Dura M, et al. Opis przypadku - Zastosowanie tomografii komputerowej wysokiej rozdzielczości w diagnostyce zmian płucnych u chorych na toczeń rumieniowaty układowy. *Reumatologia* 2014; 52(5): 339-343. (MNiSW: 5; IF: 0)
56. Jeka S. Kiedy mówimy o chorobie, a kiedy o zespole Raynauda? *Med. Dypl.* 2014; 23(7-8): 78-82. (MNiSW: 5; IF: 0)

57. Korkosz M, Gąsowski J, Leszczyński P, et al. Effect of tumour necrosis factor- $\alpha$  inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity. *Scand J Rheumatol.* 2014; 43(1): 43-48. (MNiSW: 20; IF: 2,572)
58. Korkosz M, Gąsowski J, Surdacki A, et al. Disparate effects of anti-TNF- $\alpha$  therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis. *Pharmacol Rep.* 2013; 65(4): 891-897. (MNiSW: 25; IF: 2,165)
59. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. *Ann Rheum Dis.* 2013; 72(10): 1605-1612. (MNiSW: 45; IF: 9,270)
60. Zwolakiewicz A, Sulencka-Kaatz A, Orłowicz M, et al. Opis przypadku - Osteomalacja u 41-letniej chorej w przebiegu ciężkiego niedoboru witaminy D z wtórną nadczynnością przytarczyc. *Reumatologia* 2013; 51(6): 467-470. (MNiSW: 5; IF: 0)
61. Kościńska-Ilczyszyn K, Żuchowski P, Wojciechowski R, et al. Opisy przypadków - Hemochromatoza pierwotna z zajęciem stawów. *Reumatologia* 2013; 51(4): 308-312. (MNiSW: 5; IF: 0)
62. Zwolakiewicz A, Sulencka-Kaatz A, Orłowicz M, et al. Współistnienie sarkoidozy węzłowo-płucnej i reumatoidalnego zapalenia stawów. *Reumatologia* 2013; 51(3): 221-224. (MNiSW: 5; IF: 0)
63. Korkosz M, Gąsowski J, Leszczyński P, et al. High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. *BMC Musculoskelet Disord.* 2013; 14(1): 99. (MNiSW: 25; IF: 1,898)
64. Zalewska J, Barczyńska T, Węgierska M, et al. Zaburzenia ze strony przewodu pokarmowego w przebiegu toczenia rumieniowatego układowego. *Reumatologia* 2012; 50(6): 522-528. (MNiSW: 5; IF: 0)
65. Kowalik K, Krysiński J, Białecka U, et al. Farmakoekonomiczna ocena terapii reumatoidalnego zapalenia stawów wybranymi lekami biologicznymi. *Reumatologia* 2012; 50(6): 472-477. (MNiSW: 5; IF: 0)
66. Gworys B, Jeka S, Brukiewa R, et al. Dynamics of stomach growth in the human fetal period – a postmortem study. *Int. J. Morphol.* 2012; 30(2): 461-466. (MNiSW: 15; IF: 0,213)

67. Ignaczak E, Ignaczak P, Buczkowski K, et al. The role of family physician in the diagnosis and care of patients with rheumatoid arthritis. *Forum Medycyny Rodzinnej* 2012, 168-174. (MNiSW: 4; IF: 0)
68. Jeka S, Żuchowski P, Korkosz M, et al. Probing the use of fluorescence spectroscopy as a novel diagnostic tool in patients with rheumatoid arthritis: Applicability in the detection of secondary amyloidosis. *Med Sci Monit*, 2012; 18(10): BR414-418. (MNiSW: 20; IF: 1,358)
69. Kościelniak B, Dankiewicz-Fares I, Żuchowski P, et al. The ultrasonographic manifestation of infected skeletal muscles in a patient with fulminant dermatomyositis with rhabdomyolysis. *Reumatologia* 2012; 50(3): 250-254. (MNiSW: 5; IF: 0)
70. Wiącek R, Kolossa K, Jankowski T, et al. The Efficacy and Safety of Leflunomide in Patients with Active Rheumatoid Arthritis. *Adv Clin Exp Med*. 2012; 21(3): 337-342. (MNiSW: 15; IF: 0,293)
71. Jeka S, Żuchowski P, Wojciechowski R, et al. Ultrasonografia dopplerowska i jej zastosowanie w reumatologii. *Acta Bio-Opt. Inf. Med.* 2012; 18(2): 83-87. (MNiSW: 4; IF: 0)
72. Jeka S. Reumatyzm tkanek miękkich. *Reumatologia* 2012; 50(2): 166-176. (MNiSW: 5; IF: 0)
73. Dancewicz-Fares I, Kolossa K, Kościelniak B, et al. Zmiany osteolityczne w miednicy u pacjenta z agresywną postacią łuszczycowego zapalenia stawów. *Reumatologia* 2012; 50(1): 57-60. (MNiSW: 5; IF: 0)
74. Węgierska M, Ignaczak P, Zalewska J, et al. Choroba Pageta - opis przypadku. *Ann. Acad. Med. Stetin.* 2011; 57(3): 64-69. (MNiSW: 6; IF: 0)
75. Barczyńska T, Dankiewicz-Fares I, Bilińska-Reszkowska H, et al. Nietypowa lokalizacja ziarniniaka Wegenera z zajęciem sutka – opis przypadku. *Ann. Acad. Med. Stetin.* 2011; 57(3): 70-76. (MNiSW: 6; IF: 0)
76. Jeka S, Żuchowski P, Karmowski M, et al. Review and Principles of Modern Methods of Ultrasound Imaging in Rheumatology. *Adv Clin Exp Med* 2011; 20(6): 779-785. (MNiSW: 15; IF: 0,176)
77. Balak W, Sinkiewicz W, Jeka S, et al. Nawracająca tamponada serca i posocznica u pacjenta z reumatoidalnym zapaleniem stawów. *Kardiol. Pol.* 2011; 69(9): 948-950. (MNiSW: 15; IF: 0,515)



78. Jeka S, Sokólska E, Dura M, et al. Zjawisko generowania fal harmoniczych oraz jego wykorzystanie praktyczne ze szczególnym uwzględnieniem współczesnej ultrasonografii. *Acta Bio-Opt. Inf. Med.* 2011; 2(17): 97-100. (MNiSW: 4; IF: 0)
79. Korkosz M, Gąsowski J, Grzanka P, et al. Baseline new bone formation does not predict bone loss in ankylosing spondylitis as assessed by quantitative computed tomography (QCT) - 10-year follow-up. *BMC Musculoskel. Dis.* 2011; 12: 1-7. (MNiSW: 25; IF: 1,577)
80. Maheu E, Zaim M, Appelboom T, et al. Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. *Clin Exp Rheumatol.* 2011; 29(3): 527-535. (MNiSW: 25; IF: 2,148)
81. Jeka S, Prochorec-Sobieszek M. Application of fluorescence spectroscopy in the amyloidosis diagnosis: a preliminary report. *Reumatologia* 2010; 48(4): 230-236. (MNiSW: 6; IF: 0)
82. Jeka S, Fisz J, Żuchowski P, et al. Principles of a fluorescence phenomenon. *Reumatologia* 2010; 48(4): 257-261. (MNiSW: 6; IF: 0)
83. Jeka S. Przegląd nowoczesnych technik ultrasonograficznych w reumatologii – ultrasonografia błony maziowej. *Acta Bio-Opt. Inf. Med.* 2010; 16(3): 237-240. (MNiSW: 6; IF: 0)
84. Buttgerit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. *Ann. Rheum. Dis.* 2010; 69(7): 1275-1280. (MNiSW: 32; IF: 9,082)
85. Malinowski A, Jeka S, Fus D, et al. Standardy rozwojowe dzieci i młodzieży z centralnej Polski. *Przegl. Nauk. Kult. Fiz. Uniw. Rzeszowskiego* 2009; 3: 249-260. (MNiSW: 1; IF: 0)
86. Jeka S, Murawska A. Ultrasonografia błony maziowej w chorobach reumatycznych. *Reumatologia* 2009; 47(6): 339-343. (MNiSW: 4; IF: 0)
87. Zalewska J, Ignaczak P, Bilińska-Reszkowska H, et al. Takayasu disease (Choroba Takayasu), *Reumatologia* 2009; 47(6): (MNiSW: 0; IF: 0)
88. Ignaczak P, Zalewska J, Jeka S. Nawracające zapalenie chrząstek u pacjenta z wirusowym zapaleniem wątroby typu C. *Reumatologia* 2009; 47(6): 392-395. (MNiSW: 4; IF: 0)

89. MacGregor EA, Brandes JL, Silberstein S, et al. Safety and Tolerability of Short-Term Preventive Frovatriptan: A Combined Analysis. *Headache* 2009; 49(9): 1298-314. (MNiSW: 27; IF: 2,786)
90. Alten RE, Zerbini C, Jeka S, et al. Efficacy and Safety of Pamapimod in Patients with Active Rheumatoid Arthritis Receiving Stable Methotrexate Therapy. *Ann Rheum Dis* 2010; 69: 364-367. (MNiSW: 32; IF: 9,082)
91. Nowak B, Jeka S, Wiland P, et al. Rapid and complete resolution of ascites and hydrothorax due to nephrotic syndrome caused by renal amyloidosis in a patient with juvenile chronic arthritis treated with adalimumab. *Joint Bone Spine* 2009; 76(2): 217-219. (MNiSW: 15; IF: 2,250)
92. Łukowicz M, Krakowiak H, Talar A, et al. Wzrost i masa ciała dzieci i młodzieży regionu kujawsko-pomorskiego w okresie 1988-1998. *Med. Biol. Sci.* 2007; 21(4): 99-105. (MNiSW: 3; IF: 0)
93. Buczkowski K, Ignaczak E, Czachowski S, et al. Problem komunikacji i współpracy w praktyce lekarza rodzinnego. *Probl. Med. Rodz.* 2007; 9(1): 18-24. (MNiSW: 3; IF: 0)
94. Korpikiewicz K, Lasek W, Jeka S, et al. Ocena wartości badań densytometrycznych ręki metodą DEXA w diagnostyce obrazowej wczesnego reumatoidalnego zapalenia stawów - doniesienie wstępne. *Reumatologia* 2004; 42(1): 20-30. (MNiSW: 3; IF: 0)
95. Lasek W, Rosińska-Migda J, Jeka S, et al. The usefulness of ultrasonography and hydrosonography in diagnostics of gastric pathologies in patients with history of ulcerative disease. *Pol. J. Radiol.* 2004; 69(3): 14-20. (MNiSW: 5; IF: 0)
96. Lasek W, Jeka S, Serafin Z, et al. Przydatność badań przesiewowych we wczesnym wykrywaniu chorób jąder i najądrzy, ze szczególnym uwzględnieniem raka jądra. *Ann. Acad. Med. Bydg.* 2003; 17(3): 37-41. (MNiSW: 2; IF: 0)
97. Lasek W, Pilecki S, Jeka S, et al. Wyniki badań profilaktycznych wczesnego wykrywania chorób gruczołu krokowego, ze szczególnym uwzględnieniem raka, przeprowadzonych w latach 2000-2001. *Ann. Acad. Med. Bydg.* 2003; 17(2): 31-36. (MNiSW: 2; IF: 0)
98. Janczak R, Cabrić M, Krakowiak H, et al. Cardio-pulmonary performance and the level of body fat in men of various ages. *Fizjoter. Pol.* 2002; (2): 140-144. (MNiSW: 5; IF: 0)